Drugs to enhance motor recovery after stroke

Stroke

Volumn 46, Issue 10, 2015, Pages 2998-3005

  Cramer, Steven C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drugs; Motor system; Outcomes; Recovery; Stroke

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; BIOLOGICAL MARKER; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG; SEROTONIN UPTAKE INHIBITOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; INDAN DERIVATIVE; LEVODOPA; PIPERIDINE DERIVATIVE;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; DRUG THERAPY; HUMAN; MOTOR RECOVERY; MOTOR SYSTEM; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTORATIVE THERAPY; REVIEW; CONVALESCENCE; MOTOR ACTIVITY; MOTOR PERFORMANCE; PATHOPHYSIOLOGY; STROKE;

CHOLINESTERASE INHIBITORS; DOPAMINE AGENTS; HUMANS; INDANS; LEVODOPA; MOTOR ACTIVITY; MOTOR SKILLS; PIPERIDINES; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; STROKE;

EID: 84942899205     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.007433     Document Type: Review

References (127)

1. Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24:1733-1744. doi: 10.1007/s11095-007-9324-2.
2. Cramer SC. An overview of therapies to promote repair of the brain after stroke. Head Neck. 2011;33(suppl 1):S5-S7. doi: 10.1002/hed.21840.
3. Rathore SS, Hinn AR, Cooper LS, Tyroler HA, Rosamond WD. Characterization of incident stroke signs and symptoms: fndings from the atherosclerosis risk in communities study. Stroke. 2002;33:2718-2721.
4. Gresham G, Duncan P, Stason W, Adams H, Adelman A, Alexander D, et al. Post-Stroke Rehabilitation. Rockville, MD: US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research; 1995.
5. Saposnik G, Levin M; Outcome Research Canada (SORCan) Working Group. Virtual reality in stroke rehabilitation: a meta-analysis and implications for clinicians. Stroke. 2011;42:1380-1386. doi: 10.1161/STROKEAHA.110.605451.
6. Winstein CJ, Wolf SL, Dromerick AW, Lane CJ, Nelsen MA, Lewthwaite R, et al; ICARE Investigative Team. Interdisciplinary Comprehensive Arm Rehabilitation Evaluation (ICARE): a randomized controlled trial protocol. BMC Neurol. 2013;13:5. doi: 10.1186/1471-2377-13-5.
7. Wyller TB, Sveen U, Sødring KM, Pettersen AM, Bautz-Holter E. Subjective well-being one year after stroke. Clin Rehabil. 1997;11:139-145.
8. Stewart JC, Cramer SC. Patient-reported measures provide unique insights into motor function after stroke. Stroke. 2013;44:1111-1116. doi: 10.1161/STROKEAHA.111.674671.
9. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54:743-749. doi: 10.1111/j.1532-5415.2006.00701.x.
10. Fritz S, Lusardi M. White paper: "walking speed: the sixth vital sign." J Geriatr Phys Ther. 2009;32:46-49.
11. Miller EL, Murray L, Richards L, Zorowitz RD, Bakas T, Clark P, et al; American Heart Association Council on Cardiovascular Nursing and the Stroke Council. Comprehensive overview of nursing and interdisciplinary rehabilitation care of the stroke patient: a scientifc statement from the American Heart Association. Stroke. 2010;41:2402-2448. doi: 10.1161/STR.0b013e3181e7512b.
12. Traynor K. Dalfampridine approved for MS. Am J Health Syst Pharm. 2010;67:335. doi: 10.2146/news100015.
13. Cools R, Roberts AC, Robbins TW. Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn Sci. 2008;12:31-40. doi: 10.1016/j.tics.2007.10.011.
14. Logue SF, Gould TJ. The neural and genetic basis of executive function: attention, cognitive fexibility, and response inhibition. Pharmacol Biochem Behav. 2014;123:45-54. doi: 10.1016/j.pbb.2013.08.007.
15. Cowen P, Sherwood AC. The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. J Psychopharmacol. 2013;27:575-583. doi: 10.1177/0269881113482531.
16. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, et al. Effects of fuoxetine and maprotiline on functional recovery in post-stroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996;27:1211-1214.
17. Miyai I, Reding R. Effects of antidepressants on functional recovery following stroke. J Neuro Rehab. 1998;12:5-13.
18. Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001;50:718-729.
19. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fuoxetine treatment of post-stroke depression-a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol. 2003;250:347-351. doi: 10.1007/s00415-003-1014-3.
20. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123-130. doi: 10.1016/S1474-4422(10)70314-8.
21. Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008;299:2391-2400. doi: 10.1001/jama.299.20.2391.
22. Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010;67:187-196. doi: 10.1001/archgenpsychiatry.2009.185.
23. Mikami K, Jorge RE, Moser DJ, Arndt S, Jang M, Solodkin A, et al. Prevention of post-stroke generalized anxiety disorder, using escita-lopram or problem-solving therapy. J Neuropsychiatry Clin Neurosci. 2014;26:323-328. doi: 10.1176/appi.neuropsych.11020047.
24. Aarts N, Akoudad S, Noordam R, Hofman A, Ikram MA, Stricker BH, et al. Inhibition of serotonin reuptake by antidepressants and cerebral microbleeds in the general population. Stroke. 2014;45:1951-1957. doi: 10.1161/STROKEAHA.114.004990.
25. Hankey GJ. Selective serotonin reuptake inhibitors and risk of cerebral bleeding. Stroke. 2014;45:1917-1918. doi: 10.1161/STROKEAHA.114.005844.
26. Walker FR. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-infammatory properties and how relevant is this in the treatment of depression? Neuropharmacology. 2013;67:304-317. doi: 10.1016/j. neuropharm.2012.10.002.
27. Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord. 1997;45:19-30.
28. Cukrowicz KC, Schlegel EF, Smith PN, Jacobs MP, Van Orden KA, Paukert AL, et al. Suicide ideation among college students evidencing subclinical depression. J Am Coll Health. 2011;59:575-581. doi: 10.1080/07448481.2010.483710.
29. da Rocha e Silva CE, Alves Brasil MA, Matos do Nascimento E, de Braganca Pereira B, Andre C. Is poststroke depression a major depression? Cerebrovasc Dis. 2013; 35: 385-391.
30. Spalletta G, Ripa A, Caltagirone C. Symptom profle of DSM-IV major and minor depressive disorders in frst-ever stroke patients. Am J Geriatr Psychiatry. 2005;13:108-115. doi: 10.1176/appi.ajgp.13.2.108.
31. Saxena SK, Ng TP, Koh G, Yong D, Fong NP. Is improvement in impaired cognition and depressive symptoms in post-stroke patients associated with recovery in activities of daily living? Acta Neurol Scand. 2007;115:339-346. doi: 10.1111/j.1600-0404.2006.00751.x.
32. Maes M, Leonard B, Fernandez A, Kubera M, Nowak G, Veerhuis R, et al. (Neuro)infammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:659-663. doi: 10.1016/j.pnpbp.2011.02.019.
33. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127. doi: 10.1016/j. biopsych.2006.02.013.
34. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805-809. doi: 10.1126/science.1083328.
35. Gerdelat-Mas A, Loubinoux I, Tombari D, Rascol O, Chollet F, Simonetta-Moreau M. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Neuroimage. 2005;27:314-322. doi: 10.1016/j.neuroimage.2005.05.009.
36. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, et al. The antidepressant fuoxetine restores plasticity in the adult visual cortex. Science. 2008;320:385-388. doi: 10.1126/science.1150516.
37. Guirado R, Perez-Rando M, Sanchez-Matarredona D, Castrén E, Nacher J. Chronic fuoxetine treatment alters the structure, connectivity and plasticity of cortical interneurons. Int J Neuropsychopharmacol. 2014;17:1635-1646. doi: 10.1017/S1461145714000406.
38. Perrier JF, Cotel F. Serotonergic modulation of spinal motor control. Curr Opin Neurobiol. 2014;33C:1-7. doi: 10.1016/j.conb.2014.12.008.
39. Tritsch NX, Sabatini BL. Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron. 2012;76:33-50. doi: 10.1016/j. neuron.2012.09.023.
40. McAllister TW. Polymorphisms in genes modulating the dopamine system: do they inf luence outcome and response to medication after traumatic brain injury? J Head Trauma Rehabil. 2009;24:65-68. doi: 10.1097/HTR.0b013e3181996e6b.
41. Molina-Luna K, Pekanovic A, Röhrich S, Hertler B, Schubring-Giese M, Rioult-Pedotti MS, et al. Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. PLoS One. 2009;4:e7082. doi: 10.1371/journal.pone.0007082.
42. Hosp JA, Pekanovic A, Rioult-Pedotti MS, Luft AR. Dopaminergic projections from midbrain to primary motor cortex mediate motor skill learning. J Neurosci. 2011;31:2481-2487. doi: 10.1523/JNEUROSCI.5411-10.2011.
43. Scheidtmann K, Fries W, Müller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet. 2001;358:787-790. doi: 10.1016/S0140-6736(01)05966-9.
44. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7:35-49.
45. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES. Cerebral metabolism of 6-[18F]fuoro-L-3, 4-dihydroxyphenylalanine in the primate. J Neurochem. 1987;48:1077-1082.
46. Doshi PS, Edwards DJ. Effects of L-dopa on dopamine and norepi-nephrine concentrations in rat brain assessed by gas chromatography. J Chromatogr. 1981;210:505-511.
47. Everett GM, Borcherding JW. L-dopa: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science. 1970;168:849-850. doi: 10.1126/science.168.3933.849.
48. Small SL. Pharmacotherapy of aphasia. A critical review. Stroke. 1994;25:1282-1289.
49. Floel A, Hummel F, Breitenstein C, Knecht S, Cohen LG. Dopaminergic effects on encoding of a motor memory in chronic stroke. Neurology. 2005;65:472-474. doi: 10.1212/01.wnl.0000172340.56307.5e.
50. Cramer SC, Dobkin BH, Noser EA, Rodriguez RW, Enney LA. Randomized, placebo-controlled, double-blind study of ropini-role in chronic stroke. Stroke. 2009;40:3034-3038. doi: 10.1161/STROKEAHA.109.552075.
51. Restemeyer C, Weiller C, Liepert J. No effect of a levodopa single dose on motor performance and motor excitability in chronic stroke. A double-blind placebo-controlled cross-over pilot study. Restor Neurol Neurosci. 2007;25:143-150.
52. Sonde L, Lökk J. Effects of amphetamine and/or L-dopa and physiotherapy after stroke-a blinded randomized study. Acta Neurol Scand. 2007;115:55-59. doi: 10.1111/j.1600-0404.2006.00728.x.
53. Pearson-Fuhrhop KM, Minton B, Acevedo D, Shahbaba B, Cramer SC. Genetic variation in the human brain dopamine system infuences motor learning and its modulation by L-Dopa. PLoS One. 2013;8:e61197. doi: 10.1371/journal.pone.0061197.
54. Pearson-Fuhrhop KM, Dunn EC, Mortero S, Devan WJ, Falcone GJ, Lee P, et al. Dopamine genetic risk score predicts depressive symptoms in healthy adults and adults with depression. PLoS One. 2014;9:e93772. doi: 10.1371/journal.pone.0093772.
55. Pearson-Fuhrhop KM, Cramer SC. Pharmacogenetics of neural injury recovery. Pharmacogenomics. 2013;14:1635-1643. doi: 10.2217/pgs.13.152.
56. Sesack SR, Grace AA. Cortico-Basal Ganglia reward network: micro-circuitry. Neuropsychopharmacology. 2010;35:27-47. doi: 10.1038/npp.2009.93.
57. Abe M, Schambra H, Wassermann EM, Luckenbaugh D, Schweighofer N, Cohen LG. Reward improves long-term retention of a motor memory through induction of offine memory gains. Curr Biol. 2011;21:557-562. doi: 10.1016/j.cub.2011.02.030.
58. Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron. 2012;76:470-485. doi: 10.1016/j. neuron.2012.10.021.
59. Costa RM. Plastic corticostriatal circuits for action learning: what's dopamine got to do with it? Ann N Y Acad Sci. 2007;1104:172-191. doi: 10.1196/annals.1390.015.
60. Surmeier DJ, Plotkin J, Shen W. Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. Curr Opin Neurobiol. 2009;19:621-628. doi: 10.1016/j.conb.2009.10.003.
61. Garland T Jr, Schutz H, Chappell MA, Keeney BK, Meek TH, Copes LE, et al. The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives. J Exp Biol. 2011;214(pt 2):206-229. doi: 10.1242/jeb.048397.
62. Merzenich MM, Van Vleet TM, Nahum M. Brain plasticity-based therapeutics. Front Hum Neurosci. 2014;8:385. doi: 10.3389/fnhum.2014.00385.
63. Beltran EJ, Papadopoulos CM, Tsai SY, Kartje GL, Wolf WA. Long-term motor improvement after stroke is enhanced by short-term treatment with the alpha-2 antagonist, atipamezole. Brain Res. 2010;1346:174-182. doi: 10.1016/j.brainres.2010.05.063.
64. Zittel S, Weiller C, Liepert J. Reboxetine improves motor function in chronic stroke. A pilot study. J Neurol. 2007;254:197-201. doi: 10.1007/s00415-006-0326-5.
65. Wang LE, Fink GR, Diekhoff S, Rehme AK, Eickhoff SB, Grefkes C. Noradrenergic enhancement improves motor network connectivity in stroke patients. Ann Neurol. 2011;69:375-388. doi: 10.1002/ana.22237.
66. Luria A. The restoration of motor functions after brain injury. In: Luria A, ed. Restoration of Function After Brain Injury. New York, NY: The Macmillan Company; 1963:78-116.
67. Whyte EM, Lenze EJ, Butters M, Skidmore E, Koenig K, Dew MA, et al. An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. Cerebrovasc Dis. 2008;26:317-321. doi: 10.1159/000149580.
68. Barrett KM, Brott TG, Brown RD Jr, Carter RE, Geske JR, Graff-Radford NR, et al; Mayo Acute Stroke Trial for Enhancing Recovery (MASTER) Study Group. Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase IIA clinical trial. J Stroke Cerebrovasc Dis. 2011;20:177-182. doi: 10.1016/j.jstrokecerebrovasdis.2010.12.009.
69. Berthier ML, Green C, Higueras C, Fernández I, Hinojosa J, Martín MC. A randomized, placebo-controlled study of donepezil in post-stroke aphasia. Neurology. 2006;67:1687-1689. doi: 10.1212/01. wnl.0000242626.69666.e2.
70. Crisostomo EA, Duncan PW, Propst M, Dawson DV, Davis JN. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann Neurol. 1988;23:94-97. doi: 10.1002/ana.410230117.
71. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke. 1995;26:2254-2259.
72. Walker-Batson D, Curtis S, Natarajan R, Ford J, Dronkers N, Salmeron E, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke. 2001;32:2093-2098.
73. Gladstone DJ, Danells CJ, Armesto A, McIlroy WE, Staines WR, Graham SJ, et al; Subacute Therapy with Amphetamine and Rehabilitation for Stroke Study Investigators. Physiotherapy coupled with dextroam-phetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. Stroke. 2006;37:179-185. doi: 10.1161/01.STR.0000195169.42447.78.
74. Walker-Batson D, Mehta J, Smith P, Johnson M. Amphetamine and other pharmacological agents in human and animal studies of recovery from stroke [published online ahead of print April 18, 2015]. Prog Neuropsychopharmacol Biol Psychiatry. doi: 10.1016/j.pnpbp.2015.04.002.
75. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science. 1982;217:855-857.
76. Goldstein LB. Common drugs may infuence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators. Neurology. 1995;45:865-871.
77. Bütefsch CM, Davis BC, Wise SP, Sawaki L, Kopylev L, Classen J, et al. Mechanisms of use-dependent plasticity in the human motor cortex. Proc Natl Acad Sci USA. 2000;97:3661-3665. doi: 10.1073/pnas.050350297.
78. Conroy B, Zorowitz R, Horn SD, Ryser DK, Teraoka J, Smout RJ. An exploration of central nervous system medication use and outcomes in stroke rehabilitation. Arch Phys Med Rehabil. 2005;86(12 suppl 2):S73-S81. doi: 10.1016/j.apmr.2005.08.129.
79. Cramer SC. Issues in clinical trial methodology for brain repair after stroke. In: Cramer SC, Nudo RJ, eds. Brain Repair After Stroke. Cambridge, UK: Cambridge University Press; 2010:173-182.
80. Overman JJ, Carmichael ST. Plasticity in the injured brain: more than molecules matter. Neuroscientist. 2014;20:15-28. doi: 10.1177/1073858413491146.
81. Cramer SC. Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery. Ann Neurol. 2008;63:272-287. doi: 10.1002/ana.21393.
82. Li S, Carmichael ST. Growth-associated gene and protein expression in the region of axonal sprouting in the aged brain after stroke. Neurobiol Dis. 2006;23:362-373. doi: 10.1016/j.nbd.2006.03.011.
83. Cramer SC, Chopp M. Recovery recapitulates ontogeny. Trends Neurosci. 2000;23:265-271.
84. Biernaskie J, Chernenko G, Corbett D. Effcacy of rehabilitative experience declines with time after focal ischemic brain injury. J Neurosci. 2004;24:1245-1254. doi: 10.1523/JNEUROSCI.3834-03.2004.
85. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic beneft of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32:1005-1011.
86. Ren J, Kaplan PL, Charette MF, Speller H, Finklestein SP. Time window of intracisternal osteogenic protein-1 in enhancing functional recovery after stroke. Neuropharmacology. 2000;39:860-865.
87. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology. 2000;39:1483-1494.
88. Kozlowski DA, Jones TA, Schallert T. Pruning of dendrites and restoration of function after brain damage: role of the NMDA receptor. Restor Neurol Neurosci. 1994;7:119-126. doi: 10.3233/RNN-1994-7207.
89. Narasimhan P, Liu J, Song YS, Massengale JL, Chan PH. VEGF Stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral endo-thelial cells after ischemic conditions. Stroke. 2009;40:1467-1473. doi: 10.1161/STROKEAHA.108.534644.
90. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke. 2007;38(2 suppl):748-752. doi: 10.1161/01.STR.0000253500.32979.d1.
91. Wolf SL, Winstein CJ, Miller JP, Taub E, Uswatte G, Morris D, et al; EXCITE Investigators. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA. 2006;296:2095-2104. doi: 10.1001/jama.296.17.2095.
92. Duncan PW, Sullivan KJ, Behrman AL, Azen SP, Wu SS, Nadeau SE, et al; LEAPS Investigative Team. Body-weight-supported treadmill rehabilitation after stroke. N Engl J Med. 2011;364:2026-2036. doi: 10.1056/NEJMoa1010790.
93. García-Alías G, Barkhuysen S, Buckle M, Fawcett JW. Chondroitinase ABC treatment opens a window of opportunity for task-specifc rehabilitation. Nat Neurosci. 2009;12:1145-1151. doi: 10.1038/nn.2377.
94. Cramer SC, Sur M, Dobkin BH, O'Brien C, Sanger TD, Trojanowski JQ, et al. Harnessing neuroplasticity for clinical applications. Brain. 2011;134(pt 6):1591-1609. doi: 10.1093/brain/awr039.
95. Fang PC, Barbay S, Plautz EJ, Hoover E, Strittmatter SM, Nudo RJ. Combination of NEP 1-40 treatment and motor training enhances behavioral recovery after a focal cortical infarct in rats. Stroke. 2010;41:544-549. doi: 10.1161/STROKEAHA.109.572073.
96. Starkey ML, Schwab ME. Anti-Nogo-A and training: can one plus one equal three? Exp Neurol. 2012;235:53-61. doi: 10.1016/j. expneurol.2011.04.008.
97. Hovda DA, Fenney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. Brain Res. 1984;298:358-361.
98. Adkins-Muir DL, Jones TA. Cortical electrical stimulation combined with rehabilitative training: enhanced functional recovery and dendritic plasticity following focal cortical ischemia in rats. Neurol Res. 2003;25:780-788. doi: 10.1179/016164103771953853.
99. Adkins DL, Hsu JE, Jones TA. Motor cortical stimulation promotes synaptic plasticity and behavioral improvements following senso-rimotor cortex lesions. Exp Neurol. 2008;212:14-28. doi: 10.1016/j. expneurol.2008.01.031.
100. Johansson BB. Brain plasticity and stroke rehabilitation. The Willis lecture. Stroke. 2000;31:223-230.
101. Riley JD, Le V, Der-Yeghiaian L, See J, Newton JM, Ward NS, et al. Anatomy of stroke injury predicts gains from therapy. Stroke. 2011;42:421-426. doi: 10.1161/STROKEAHA.110.599340.
102. Stinear CM, Barber PA, Petoe M, Anwar S, Byblow WD. The PREP algorithm predicts potential for upper limb recovery after stroke. Brain. 2012;135(pt 8):2527-2535. doi: 10.1093/brain/aws146.
103. Burke Quinlan E, Dodakian L, See J, McKenzie A, Le V, Wojnowicz M, et al. Neural function, injury, and stroke subtype predict treatment gains after stroke. Ann Neurol. 2015;77:132-145. doi: 10.1002/ana.24309.
104. Kato M, Serretti A. Review and meta-analysis of antidepressant phar-macogenetic fndings in major depressive disorder. Mol Psychiatry. 2010;15:473-500. doi: 10.1038/mp.2008.116.
105. Kohen R, Cain KC, Buzaitis A, Johnson V, Becker KJ, Teri L, et al. Response to psychosocial treatment in poststroke depression is associated with serotonin transporter polymorphisms. Stroke. 2011;42:2068-2070.
106. Kleim JA, Bruneau R, Van den Berg P, MacDonald E, Mulrooney R, Pocock D. Motor cortex stimulation enhances motor recovery and reduces peri-infarct dysfunction following ischemic insult. Neurol Res. 2003;25:789-793. doi: 10.1179/016164103771953862.
107. Plautz EJ, Barbay S, Frost SB, Friel KM, Dancause N, Zoubina E V, et al. Post-infarct cortical plasticity and behavioral recovery using concurrent cortical stimulation and rehabilitative training: a feasibility study in primates. Neurol Res. 2003;25:801-810. doi: 10.1179/016164103771953880.
108. Teskey GC, Flynn C, Goertzen CD, Monfls MH, Young NA. Cortical stimulation improves skilled forelimb use following a focal ischemic infarct in the rat. Neurol Res. 2003;25:794-800. doi: 10.1179/016164103771953871.
109. Levy RM, Harvey RL, Kissela BM, Winstein CJ, Lutsep HL, Parrish TB, et al. Epidural electrical stimulation for stroke rehabilitation: results of the prospective, multicenter, randomized, single-blinded everest trial [published online ahead of print March 6, 2015]. Neurorehabil Neural Repair. pii: 1545968315575613.
110. Nouri S, Cramer SC. Anatomy and physiology predict response to motor cortex stimulation after stroke. Neurology. 2011;77:1076-1083. doi: 10.1212/WNL.0b013e31822e1482.
111. Cramer SC, Koroshetz WJ, Finklestein SP. The case for modality-specifc outcome measures in clinical trials of stroke recovery-promoting agents. Stroke. 2007;38:1393-1395. doi: 10.1161/01.STR.0000260087. 67462.80.
112. Salbach NM, Mayo NE, Higgins J, Ahmed S, Finch LE, Richards CL. Responsiveness and predictability of gait speed and other disability measures in acute stroke. Arch Phys Med Rehabil. 2001;82:1204-1212. doi: 10.1053/apmr.2001.24907.
113. Perry J, Garrett M, Gronley JK, Mulroy SJ. Classifcation of walking handicap in the stroke population. Stroke. 1995;26:982-989.
114. Prasad A, Kumar SS, Dessimoz C, Bleuler S, Laule O, Hruz T, et al. Global regulatory architecture of human, mouse and rat tissue transcriptomes. BMC Genomics. 2013;14:716. doi: 10.1186/1471-2164-14-716.
115. Chan ET, Quon GT, Chua G, Babak T, Trochesset M, Zirngibl RA, et al. Conservation of core gene expression in vertebrate tissues. J Biol. 2009;8:33. doi: 10.1186/jbiol130.
116. Cramer SC. Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol. 2008;63:549-560. doi: 10.1002/ana.21412.
117. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for industry. Clinical studies section of labeling for human prescription drug and biological products-content and format. http://www. Fda.Gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm075059.Pdf. Published January 2006. Accessed July 11, 2015.
118. Temple R. A regulatory authority's opinion about surrogate endpoints. In: Nimmo W, Tucker G, eds. Clinical Measurement in Drug Evaluation. New York: J. Wiley; 1995:3-22.
119. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605-613.
120. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA. 1999;282:771-778.
121. Dijkhuizen RM, van der Marel K, Otte WM, Hoff EI, van der Zijden JP, van der Toorn A, et al. Functional MRI and diffusion tensor imaging of brain reorganization after experimental stroke. Transl Stroke Res. 2012;3:36-43. doi: 10.1007/s12975-011-0143-8.
122. Tardy J, Pariente J, Leger A, Dechaumont-Palacin S, Gerdelat A, Guiraud V, et al. Methylphenidate modulates cerebral post-stroke reorganization. Neuroimage. 2006;33:913-922. doi: 10.1016/j.neuroimage. 2006.07.014.
123. Burke E, Cramer SC. Biomarkers and predictors of restorative therapy effects after stroke. Curr Neurol Neurosci Rep. 2013;13:329. doi: 10.1007/s11910-012-0329-9.
124. Lang CE, Macdonald JR, Reisman DS, Boyd L, Jacobson Kimberley T, Schindler-Ivens SM, et al. Observation of amounts of movement practice provided during stroke rehabilitation. Arch Phys Med Rehabil. 2009;90:1692-1698. doi: 10.1016/j.apmr.2009.04.005.
125. Zorowitz RD, Smout RJ, Gassaway JA, Horn SD. Neurostimulant medication usage during stroke rehabilitation: the Post-Stroke Rehabilitation Outcomes Project (PSROP). Top Stroke Rehabil. 2005;12:28-36. doi: 10.1310/2403-B0CY-1UDN-4B6D.
126. See J, Dodakian L, Chou C, Chan V, McKenzie A, Reinkensmeyer DJ, et al. A standardized approach to the Fugl-Meyer assessment and its implications for clinical trials. Neurorehabil Neural Repair. 2013;27:732-741. doi: 10.1177/1545968313491000.
127. Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol. 2012;11:369-380. doi: 10.1016/S1474-4422(12)70039-X.